Business World |

Catastrophe! The verdict of the experts gathered yesterday on behalf of the Health Authority (FDA) on Naproxcinod NicOx is clear: sixteen votes to one against, they voted against the authorization for the U.S. market for treatment cons osteoarthritis.

If the FDA ultimately decides the approval of a drug in the United States, the Advisory Committee constitutes a notice of weight, especially when it is so decided. The agency should make its decision before July 24 next.

But already, the hopes were so meager that the actions d?grindolent Stock Exchange Thursday, while trading in securities listed in NicOx 9:00, after being suspended Wednesday from 2:00 p.m. at the request of the company. At the close of the Paris Bourse during the uncoupling of 44.53% to 2.9 euros.On Tuesday, the day the group announced this biotechnology application to stay the course, the shares had already fallen from 28.37%.

Total, in three sessions, NicOx has lost more than half its value.

The continuation of the project Naproxcinod compromised

The President's Advisory Committee meeting Wednesday, Dr. Kathleen O'Neil, summarizing the conclusions of the Advisory Committee meeting, said extant 'enthusiasm about the potential of naproxcinod but that additional data from additional studies on job security would be needed, "reports the group in a statement.

This single sentence has made it clear to investors that the case is wrong party.According to analysts at Natixis, the American drug agency should provide to NicOx a "Complete Response Letter" means not permitted, requiring further study to clarify the gray areas of the record, particularly in terms of job security product.

Now "option to initiate studies on the long term is virtually impossible for NicOx," according to them. This would require large patient populations over periods of several years of testing, an expensive option that NicOx should not continue, they said. Natixis is passed directly on Thursday morning of the recommendation to "buy" to "ease".

A big blow for NicOx, which had very high expectations of this product across the Atlantic.Analysts said the potential of the drug could reach 1.3 billion euros of sales at the peak of sales, in 2017.

ALSO READ:

"NicOx drug lighthouse on the hot seat in the U.S.

• After the solar Mersen diversified into health
• The national debt passes the threshold of 1.5 trillion
• The Cac 40 expected to be closer to 3900 points
• The stock markets under pressure, the Cac lost more than 2%
• The Paris Bourse is stabilizing in positive territory